von Willebrand Factor Brand Name
What is von Willebrand Factor
von Willebrand factor is recombinant von Willebrand factor indicated for on-demand treatment, control of bleeding episodes, and perioperative management of bleeding in adults with von Willebrand disease.
During clinical trials, all bleeding episodes (n = 193) treated with von Willebrand factor alone or von Willebrand factor and factor VIII were controlled with an efficacy rating of excellent (96.9%) or good (3.1%).
Most bleeds (81.8%) were resolved with a single infusion.
During perioperative management, overall hemostatic efficacy 24 hours after the last perioperative infusion or at completion of study visit, whichever occurred earlier, for both major and minor surgeries was 100% (excellent 60% and good 40%).
Thrombotic events can occur in patients receiving von Willebrand factor; monitor vWF:RCo and factor VIII activities. Generalized pruritus, vomiting, nausea, dizziness, and vertigo were the most common adverse reactions observed during clinical trials
- surgical bleeding prophylaxis
- von Willebrand’s disease
- anaphylactoid reactions
- antibody formation
- infusion-related reactions
- injection site reaction
- sinus tachycardia
- clotting inhibitor titers
- von Willebrand’s factor activity
- factor VIII inhibitors
- hamster protein hypersensitivity
- mannitol hypersensitivity
- murine protein hypersensitivity
- polysorbate 80 hypersensitivity
- thromboembolic disease
- von Willebrand factor inhibitors
There are no drug interactions associated with von Willebrand Factor products.